Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2012
06/14/2012WO2012076694A1 Cancer gene therapy using nucleic acids encoding us28 and g-protein
06/14/2012WO2012076688A1 Combination comprising a derivative of the family of the combretastatins and cetuximab
06/14/2012WO2012076663A1 Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
06/14/2012WO2012076513A1 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
06/14/2012WO2012076430A1 Triazolopyridine compounds
06/14/2012WO2012076413A1 Compound for the treatment of tumours and tumour metastases
06/14/2012WO2012076190A1 Bispecific aptamers mediating tumour cell lysis
06/14/2012WO2012075957A1 Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis
06/14/2012WO2012075754A1 Pharmaceutical composition for treating acute lymphocytic leukemia
06/14/2012WO2012075683A1 [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
06/14/2012WO2012075679A1 Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
06/14/2012WO2012075581A1 Antibodies selective for cells presenting erbb2 at high density
06/14/2012WO2012059935A9 Process for preparing bendamus tine hydrochloride monohydrate
06/14/2012WO2012053741A3 Nucleic acid molecules inducing rna interference, and uses thereof
06/14/2012WO2012050303A3 Pharmaceutical composition for cancer prevention and treatment containing the c12orf59 gene or protein as an active ingredient
06/14/2012WO2012047930A3 Compositions and methods for treatment of gynecologic cancers
06/14/2012WO2012044939A3 Method of preparing a dry powder from a water bacteria extract-concentrate
06/14/2012WO2012044933A3 B and t lymphocyte attenuator marker for use in adoptive t-cell therapy
06/14/2012WO2012034116A3 Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
06/14/2012WO2012031296A3 Methods and composition for inhibiting or attenuating leukocyte-endothelial interactions
06/14/2012WO2012030854A3 Compositions and methods for modulating emt and uses thereof
06/14/2012WO2012027379A3 Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
06/14/2012WO2012007948A3 CYTOTOXIC Ti (IV) COMPOUNDS
06/14/2012WO2012006563A3 Novel daidzein analogs as treatment for cancer
06/14/2012WO2011140135A9 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
06/14/2012WO2011088462A3 Alpha-fetoprotein 'ring and tail' peptides
06/14/2012US20120149890 Polynucleotides Encoding Thymidine Kinase Mutants
06/14/2012US20120149778 Compounds
06/14/2012US20120149771 Method for treating airway hyper-responsiveness with lipoxin analogs
06/14/2012US20120149762 Gene and Protein Relating to Hepatocellular Carcinoma and Methods of Use Thereof
06/14/2012US20120149761 Nucleic acid molecules and uses thereof
06/14/2012US20120149755 Antisense oligonucleotide modulation of raf gene expression
06/14/2012US20120149744 Anti-mitotic anti-proliferative compounds
06/14/2012US20120149738 Novel inhibitors of proliferation and activation of signal transducer and activators of transcription (stats)
06/14/2012US20120149736 Enzyme inhibitors
06/14/2012US20120149733 Piperidinyl compound as a modulator of chemokine receptor activity
06/14/2012US20120149732 Multifunctional linkers and methods for the use thereof
06/14/2012US20120149729 Metalloenzyme inhibitor compounds
06/14/2012US20120149726 Crystal Forms of Kinase Inhibitors
06/14/2012US20120149722 Heteroaryl compounds and uses thereof
06/14/2012US20120149707 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same
06/14/2012US20120149701 Certain chemical entities, compositions and methods
06/14/2012US20120149700 2-cyanophenyl fused heterocyclic compounds, and compostions and uses thereof
06/14/2012US20120149696 Ethylene diamine modulators of fatty acid hydrolase
06/14/2012US20120149694 Substituted piperidines
06/14/2012US20120149693 Therapeutic compounds
06/14/2012US20120149691 Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors
06/14/2012US20120149687 Heterocyclic compounds and uses thereof
06/14/2012US20120149686 Kinase inhibitors and method of treating cancer with same
06/14/2012US20120149684 Akt inhibitors
06/14/2012US20120149682 Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
06/14/2012US20120149681 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
06/14/2012US20120149680 Kinase inhibitors
06/14/2012US20120149678 Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto
06/14/2012US20120149671 17alpha, 21-dihydroxypregnene esters as antiandrogenic agents
06/14/2012US20120149670 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
06/14/2012US20120149669 22-Haloacetoxy-Homopregnacalciferol Analogs and Their Uses
06/14/2012US20120149665 Combination therapy for treating proliferative diseases
06/14/2012US20120149663 Boronic acid compositions and methods related to cancer
06/14/2012US20120149662 Heterocyclic Compounds as Janus Kinase Inhibitors
06/14/2012US20120149661 Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
06/14/2012US20120149660 Novel n-substituted 5-hydroxypyrollindes as inhibitors of mdm2-p53 interactions
06/14/2012US20120149658 Modified pectins, compositions and methods related thereto
06/14/2012US20120149657 2'-fluoro arabino nucleosides and use thereof
06/14/2012US20120149656 WATER SOLUTION OF 20(R) - GINSENOSIDE Rg3 PHARMACEUTICAL COMPOSITION AND PROCESS THEREOF
06/14/2012US20120149651 Caveolin peptides and their use as therapeutics
06/14/2012US20120149648 Therapeutic peptidomimetic macrocycles
06/14/2012US20120149647 Methods for Assessing the Efficacy of Gemcitabine or Ara-C Treatment of Cancer Using Human Antigen R Levels
06/14/2012US20120149640 Peptides modulating the activity of igf-1 and the applications of said peptides
06/14/2012US20120148676 Artificial cell constructs for cellular manipulation
06/14/2012US20120148663 Lipophilic drug carrier
06/14/2012US20120148661 High bioavailability oral picoplatin anti-cancer therapy
06/14/2012US20120148654 Method and system for a photoresist-based immunoisolative microcontainer with nanoslots defined by nanoimprint lithography
06/14/2012US20120148628 Compositions and methods for treatment of cancer
06/14/2012US20120148627 Compositions and Methods for Treatment of Neoplastic Disease
06/14/2012US20120148613 Multivalent entrain-and-amplify immunotherapeutics for carcinoma
06/14/2012US20120148611 Cyclophosphamide in Combination with Anti-Idiotypic Vaccines
06/14/2012US20120148610 Monomethylvaline compounds capable of conjugation to ligands
06/14/2012US20120148607 Anti c-met antibodies
06/14/2012US20120148602 Cancer Treatment With Endothelin Receptor Antagonists
06/14/2012US20120148598 Methods for treating a tumor using an antibody that specifically binds grp94
06/14/2012US20120148597 Human monoclonal antibodies to ctla-4
06/14/2012US20120148595 Gaba-linked anthracycline-lipid conjugates
06/14/2012US20120148592 Neutralizing anti-ccl20 antibodies
06/14/2012US20120148589 Human cancer-related gene, its encoded products and applications
06/14/2012US20120148587 Polypeptide formulation
06/14/2012US20120148584 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the threatment of early stage tumors
06/14/2012US20120148582 Engineered anti-il-23r antibodies
06/14/2012US20120148579 Antibodies to ox-2/cd200 and uses thereof
06/14/2012US20120148577 Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
06/14/2012US20120148576 Humanized anti-cd 19 antibody formulations
06/14/2012US20120148572 Novel antibodies
06/14/2012US20120148569 Picrorhiza kurroa extract for prevention, elimination and treatment of infection diseases
06/14/2012US20120148567 Particulate hyaluronic acid formulations for cellular delivery of bioactive agents
06/14/2012US20120148564 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
06/14/2012US20120148561 Use of runx3 and mir-532-5p as cancer markers and therapeutic targets
06/14/2012US20120148555 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
06/14/2012US20120148553 Methods of generating natural killer cells
06/14/2012US20120148552 Method and compositions for enhanced anti-tumor effector functioning of t cells
06/14/2012US20120148540 Proliferated cell lines and uses thereof
1 ... 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 ... 2211